captopril has been researched along with Metabolic Syndrome in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (72.73) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bastacky, SI; Jackson, EK; Salah, EM; Tofovic, SP | 1 |
| Ackerman, Z; Amir, G; Grozovski, M; Oron-Herman, M; Rosenthal, T; Sela, BA | 1 |
| Borghi, C; Napoli, C; Omboni, S | 1 |
| Ambrosioni, E; Borghi, C; Cicero, AF | 1 |
| Johnson, RJ; Mu, W; Nakagawa, T; Reungjui, S; Roncal, CA; Sánchez-Lozada, LG; Sautin, YY | 1 |
| Oron-Herman, M; Rosenthal, T; Sela, BA | 1 |
| Mirelman, D; Miron, T; Oron-Herman, M; Rabinkov, A; Rosenthal, T; Sela, BA; Wilchek, M | 1 |
| Cao, TB; Li, ZB; Liu, DY; Ma, LQ; Wang, LJ; Zhang, LL; Zhang, YP; Zhu, ZM | 1 |
| Medvedev, IN; Simonenko, VB; Tolmachev, VV | 1 |
| Ernsberger, P; Johnson, JL; Koletsky, RJ; Mirelman, D; Rosenthal, T | 1 |
| Ackerman, Z; Grozovski, M; Link, G; Oron-Herman, M; Pappo, O; Rosenthal, T; Sela, BA | 1 |
2 trial(s) available for captopril and Metabolic Syndrome
| Article | Year |
|---|---|
Fixed-dose combination of zofenopril plus hydrochlorothiazide vs. irbesartan plus hydrochlorothiazide in hypertensive patients with established metabolic syndrome uncontrolled by previous monotherapy. The ZAMES study (Zofenopril in Advanced MEtabolic Synd
Topics: Aged; Biphenyl Compounds; Captopril; Female; Humans; Hydrochlorothiazide; Irbesartan; Male; Metabolic Syndrome; Middle Aged; Tetrazoles | 2016 |
Effects of early treatment with zofenopril in patients with myocardial infarction and metabolic syndrome: the SMILE Study.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Captopril; Comorbidity; Female; Heart Failure; Humans; Incidence; Male; Metabolic Syndrome; Middle Aged; Myocardial Infarction | 2008 |
9 other study(ies) available for captopril and Metabolic Syndrome
| Article | Year |
|---|---|
Captopril Attenuates Cardiovascular and Renal Disease in a Rat Model of Heart Failure With Preserved Ejection Fraction.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Captopril; Comorbidity; Disease Models, Animal; Diuretics; Drug Therapy, Combination; Furosemide; Glomerular Filtration Rate; Heart Failure; Kidney; Male; Metabolic Syndrome; Rats, Zucker; Renal Circulation; Renal Insufficiency, Chronic; Renin-Angiotensin System; Stroke Volume; Ventricular Function, Left; Ventricular Pressure | 2018 |
Effects of antihypertensive and triglyceride lowering agents on splenocyte apoptosis in rats with fatty liver.
Topics: Amlodipine; Animals; Antihypertensive Agents; Apoptosis; Bezafibrate; Blood Pressure; Captopril; Caspase 3; Fatty Liver; Hypolipidemic Agents; Lipids; Male; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Rats; Rats, Sprague-Dawley; Spleen; Triglycerides | 2013 |
Combination of captopril and allopurinol retards fructose-induced metabolic syndrome.
Topics: Allopurinol; Angiotensin-Converting Enzyme Inhibitors; Animal Feed; Animals; Antimetabolites; Body Weight; Captopril; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Energy Metabolism; Fructose; Insulin Resistance; Male; Metabolic Syndrome; Rats; Rats, Sprague-Dawley | 2009 |
Risk reduction therapy for syndrome X: comparison of several treatments.
Topics: Amlodipine; Animals; Antihypertensive Agents; Bezafibrate; Blood Pressure; Body Weight; Captopril; Fructose; Hydrolases; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Metabolic Syndrome; Rats; Rats, Sprague-Dawley; Risk Reduction Behavior; Rosiglitazone; Thiazolidinediones; Triglycerides | 2005 |
The effects of S-allylmercaptocaptopril, the synthetic product of allicin and captopril, on cardiovascular risk factors associated with the metabolic syndrome.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Captopril; Cyclopropanes; Disease Models, Animal; Disulfides; Homocysteine; Hypertension; Hypoglycemic Agents; Insulin; Male; Metabolic Syndrome; Rats; Rats, Sprague-Dawley; Risk Factors; Sulfinic Acids; Treatment Outcome; Triglycerides | 2005 |
[Renin-angiotensin system in mesenteric adipose tissues in rats with metabolic syndrome].
Topics: Adipocytes; Adipose Tissue; Angiotensin II; Angiotensinogen; Animals; Benzimidazoles; Biphenyl Compounds; Calcium; Captopril; Cells, Cultured; Male; Metabolic Syndrome; Peptidyl-Dipeptidase A; Rats; Rats, Wistar; Receptor, Angiotensin, Type 2; Renin-Angiotensin System; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tetrazoles | 2006 |
[Comparative evaluation of the influence of sulfhydryl and phosphate ACE inhibitors on thrombocyte aggregation in patients suffering from atrerial hypertension with metabolic syndrome].
Topics: Angiotensin-Converting Enzyme Inhibitors; Captopril; Female; Fosinopril; Humans; Hypertension; Male; Metabolic Syndrome; Platelet Activating Factor | 2007 |
Therapeutic actions of allylmercaptocaptopril and captopril in a rat model of metabolic syndrome.
Topics: Administration, Oral; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Glucose; Blood Pressure; Captopril; Disease Models, Animal; Disulfides; Dose-Response Relationship, Drug; Drug Combinations; Female; Hypoglycemic Agents; Insulin; Male; Metabolic Syndrome; Rats; Rats, Inbred SHR; Sulfinic Acids; Treatment Outcome | 2007 |
Effects of amlodipine, captopril, and bezafibrate on oxidative milieu in rats with fatty liver.
Topics: Amlodipine; Animals; Antihypertensive Agents; Bezafibrate; Captopril; Fatty Liver; Fructose; Hypolipidemic Agents; Male; Metabolic Syndrome; Oxidative Stress; Rats; Rats, Sprague-Dawley | 2008 |